Log in

NASDAQ:KERX - Keryx Biopharmaceuticals Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume2.60 million shs
Average Volume1.69 million shs
Market Capitalization$344.00 million
P/E RatioN/A
Dividend YieldN/A
Beta2.35
Keryx Biopharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:KERX
CUSIP49251510
Phone617-466-3500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$60.64 million
Book Value($0.12) per share

Profitability

Net Income$-163,440,000.00

Miscellaneous

EmployeesN/A
Market Cap$344.00 million
Next Earnings DateN/A
OptionableOptionable

Receive KERX News and Ratings via Email

Sign-up to receive the latest news and ratings for KERX and its competitors with MarketBeat's FREE daily newsletter.


Keryx Biopharmaceuticals (NASDAQ:KERX) Frequently Asked Questions

What is Keryx Biopharmaceuticals' stock symbol?

Keryx Biopharmaceuticals trades on the NASDAQ under the ticker symbol "KERX."

How were Keryx Biopharmaceuticals' earnings last quarter?

Keryx Biopharmaceuticals (NASDAQ:KERX) issued its quarterly earnings data on Thursday, November, 8th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.15) by $0.01. The biopharmaceutical company earned $28.04 million during the quarter, compared to analyst estimates of $29.56 million. View Keryx Biopharmaceuticals' Earnings History.

Has Keryx Biopharmaceuticals been receiving favorable news coverage?

News stories about KERX stock have trended neutral recently, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Keryx Biopharmaceuticals earned a daily sentiment score of 0.2 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Keryx Biopharmaceuticals.

Who are some of Keryx Biopharmaceuticals' key competitors?

What other stocks do shareholders of Keryx Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Keryx Biopharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Amyris (AMRS), Gilead Sciences (GILD), Nektar Therapeutics (NKTR), Exelixis (EXEL), Immunomedics (IMMU), Novavax (NVAX), Dynavax Technologies (DVAX), Progenics Pharmaceuticals (PGNX) and Ariad Pharmaceuticals (ARIA).

Who are Keryx Biopharmaceuticals' key executives?

Keryx Biopharmaceuticals' management team includes the folowing people:
  • Ms. Jodie Pope Morrison, Interim CEO & Director (Age 43)
  • Mr. Scott A. Holmes, CFO, Sr. VP & Treasurer (Age 44)
  • Ms. Christine A. Carberry, Sr. VP & COO (Age 57)
  • Dr. John F. Neylan, Sr. VP & Chief Medical Officer (Age 65)
  • Mr. Tony Chambers, VP of Sales

How big of a company is Keryx Biopharmaceuticals?

Keryx Biopharmaceuticals has a market capitalization of $0.00 and generates $60.64 million in revenue each year. The biopharmaceutical company earns $-163,440,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis. View Additional Information About Keryx Biopharmaceuticals.

What is Keryx Biopharmaceuticals' official website?

The official website for Keryx Biopharmaceuticals is http://www.keryx.com/.

How can I contact Keryx Biopharmaceuticals?

Keryx Biopharmaceuticals' mailing address is ONE MARINA PARK DR., BOSTON MA, 02210. The biopharmaceutical company can be reached via phone at 617-466-3500 or via email at [email protected]


MarketBeat Community Rating for Keryx Biopharmaceuticals (NASDAQ KERX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  505 (Vote Outperform)
Underperform Votes:  363 (Vote Underperform)
Total Votes:  868
MarketBeat's community ratings are surveys of what our community members think about Keryx Biopharmaceuticals and other stocks. Vote "Outperform" if you believe KERX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KERX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2019 by MarketBeat.com Staff

Featured Article: Blue-Chip Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel